Suppr超能文献

关于肝素辅因子II催化抑制凝血酶过程中肝素结构要求的研究。

Studies on the structural requirements of heparin for the catalysis of thrombin inhibition by heparin cofactor II.

作者信息

Sié P, Petitou M, Lormeau J C, Dupouy D, Boneu B, Choay J

机构信息

Laboratoire d'Hémostase, Centre de Transfusion Sanguine, Toulouse, France.

出版信息

Biochim Biophys Acta. 1988 Aug 11;966(2):188-95. doi: 10.1016/0304-4165(88)90111-0.

Abstract

The structural requirements of heparin for the catalysis of thrombin inhibition by heparin cofactor II (HC II) were investigated. A series of well characterized heparin derivatives were prepared and their activities were measured using human thrombin in the presence of an excess of purified human HC II and, for comparison, antithrombin III (AT III). The 50% inhibitory concentrations of each derivative were calculated and compared with those of unmodified heparin. Heparin activity was strongly dependent on molecular weight (Mr) in a manner grossly comparable for the two inhibitors. High-Mr fractions were the most active. Below 10 kDa, the activity dropped rapidly. A minimum size of 26 residues appeared to be required for HC II activation (against 16-18 for AT III). Below 5 kDa, a residual activity two orders of magnitude lower than that of high-Mr species remained with HC II (but not with AT III). Heparin was selectively desulfated or oversulfated in the O- and/or N-position. When an N-acetyl group was substituted for the original N-sulfate in the glucosamine and the derivative was oversulfated in the O-position, a strong activity with HC activities with both inhibitors decreased when the overall sulfate content (i.e., the charge density) was reduced, and vice-versa. Carboxyl-reduced heparin was also inactive but activity could be restored after O-sulfation. Our results thus suggest that, unlike the case of AT III, no functional group in heparin is critical for optimal thrombin inhibition by HC II. Sulfate and carboxylate are important in as much as they contribute to the global charge of the molecule.

摘要

研究了肝素对肝素辅因子II(HC II)催化凝血酶抑制作用的结构要求。制备了一系列特性明确的肝素衍生物,并在过量纯化的人HC II存在下,使用人凝血酶测量其活性,作为比较,还使用了抗凝血酶III(AT III)。计算了每种衍生物的50%抑制浓度,并与未修饰肝素的抑制浓度进行比较。肝素活性强烈依赖于分子量(Mr),两种抑制剂的这种依赖性大致相似。高分子量部分活性最高。低于10 kDa时,活性迅速下降。激活HC II似乎需要至少26个残基的大小(而激活AT III需要16 - 18个残基)。低于5 kDa时,HC II仍保留比高分子量物质低两个数量级的残余活性(但AT III没有)。肝素在O位和/或N位被选择性地脱硫酸或过硫酸化。当用N - 乙酰基取代葡糖胺中原有的N - 硫酸根,且衍生物在O位过硫酸化时,与HC II有很强的活性 当总硫酸含量(即电荷密度)降低时,两种抑制剂的活性均下降,反之亦然。羧基还原的肝素也无活性,但O - 硫酸化后活性可以恢复。因此,我们的结果表明,与AT III的情况不同,肝素中没有官能团对HC II最佳抑制凝血酶至关重要。硫酸根和羧基很重要,因为它们有助于分子的整体电荷。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验